Introduction {#Sec1}
============

Methamphetamine is a highly addictive stimulant, and its psychostimulant effects have been suggested to be attributable to its stimulating action on presynaptic neurons, resulting in a release of dopamine and other neurotransmitters through monoamine transporters or vesicular monoamine transporters (Barr et al. [@CR1]). Methamphetamine, having a chiral center, exists as *d*- and *l*-enantiomers and is designated as a controlled substance without discrimination of its enantiomers. The *d*-enantiomer exerts potent physiological and psychostimulant effects and has high abuse liability, whereas the *l*-enantiomer exerts almost none of these effects (Mendelson et al. [@CR6]). In clinical practice, *d*-methamphetamine is prescribed for treatment of attention-deficit/hyperactivity disorder, exogenous obesity, and narcolepsy. *l*-Methamphetamine is an active ingredient contained in a nasal decongestant (Vicks Vapor Inhaler) in the United States and is a metabolite of selegiline, a selective monoamine oxidase (MAO)-B inhibitor widely used for treatment of Parkinson's disease and depression. *l*-Methamphetamine has often been described as a molecule with pharmacological efficacy comparable to *d*-methamphetamine, likely because only a few comparative pharmacodynamic and pharmacokinetic studies have been conducted. Therefore, selegiline, sometimes ambiguously referred to as its major metabolite *l*-methamphetamine, may also induce psychostimulant effects.

The aim of the present study was to determine the efficacies of the methamphetamine enantiomers to induce psychostimulant effects, and to clarify a cause for any differences. Some pharmacological response differences are related to pharmacokinetic properties. For instance, a comparative study on *d*-methamphetamine and cocaine revealed that the slower clearance of *d*-methamphetamine contributes to the longer-lasting stimulant effects (Fowler et al. [@CR4]). Thus, in the present study, we directly compared the psychomotor effects and pharmacokinetics of the methamphetamine enantiomers in mice.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

Male ddY mice (8 weeks old, Japan SLC, Shizuoka, Japan) were kept in a facility with controlled humidity (50 ± 20%) and temperature (23 ± 2 °C) and were maintained under a 12-h light/dark cycle with free access to food (Oriental Yeast, Tokyo, Japan) and water. The mice were acclimated for 1 week before being used in the experiments.

Chemicals {#Sec4}
---------

*l*-Methamphetamine hydrochloride was prepared from benzaldehyde in our institution according to previously described methods (Paulsen-Sörman et al. [@CR8]; Posakony et al. [@CR9]). The purity of the product was \>99%. *d*-Methamphetamine hydrochloride was purchased from Dainippon Pharmaceutical (Osaka, Japan). All reagents were dissolved in saline and administered subcutaneously (s.c.).

Locomotor activity {#Sec5}
------------------

Locomotor activity was measured for 2 h post-drug administration using an infrared-linked activity sensor system (AB System-24A, Neuroscience, Tokyo). For sensitization, each mouse was treated with one of the enantiomers at an interval of 3 or 4 days, for a total of seven injections. Locomotor activity in these mice was also measured for 2 h post-drug administration.

Stereotyped behavior {#Sec6}
--------------------

The intensity of stereotyped behavior was assessed at 15-min intervals for 2 h post-drug administration using the scoring system of Costall and Naylor ([@CR3]): 0, behavior of the mouse is the same as that of a saline-treated mouse; 1, discontinuous sniffing with constant exploratory activity; 2, continuous sniffing and periodic exploratory activity; 3, continuous sniffing and discontinuous biting, gnawing or licking; 4, continuous biting, gnawing or licking, with no exploratory activity.

Pharmacokinetics {#Sec7}
----------------

A blood sample (20 μL) was collected from tail vein at indicated time points in Table [1](#Tab1){ref-type="table"}, and stored at −20 °C after centrifugation (12,000×*g*, 5 min). The striatum was dissected out 2 h after administration and stored at −80 °C. Striatal samples were homogenized in 50% acetonitrile, and centrifuged (10,400×*g*, 15 min, 4 °C). Each sample was extracted with 1-chlolobutane/acetonitrile (4/1, v/v), then with 0.5% HCl (back extraction). Amphetamine and methamphetamine concentrations were determined by liquid chromatography--tandem-mass spectrometry (Slawson et al. [@CR11]) with a Chromolith RP-18e column (Merck, Darmstadt, Germany), without chiral derivatization (Nishida et al. [@CR7]). The lower limit of quantification was 3 ng/mL, but for brain amphetamine, 1 ng/mL. The maximum plasma concentration (*C* ~max~) and the area under the plasma concentration vs. time curve from 0 to 2 or 4 h (AUC~0--2h~ or AUC~0--4h~) were calculated using WinNonlin software version 6.4 (Certara, NJ, USA).

Statistical analysis {#Sec8}
--------------------

Statistical analyses were performed using one-way analysis of variance with SPSS Statistics software (IBM Corp., NY, USA), followed by Dunnett's test (locomotor activity and stereotypy), the Bonferroni correction (sensitization), or Student's *t* test (pharmacokinetics). Differences were considered statistically significant at values of *P* \< 0.05.

Results {#Sec9}
=======

Comparison of methamphetamine enantiomer-induced psychomotor effects {#Sec10}
--------------------------------------------------------------------

Subcutaneous administration of *l*-methamphetamine at doses of 1--10 mg/kg did not significantly increase locomotor activity in mice (Fig. [1](#Fig1){ref-type="fig"}a). By contrast, administration of *d*-methamphetamine at doses of 1--3 mg/kg led to dose-dependent increases in locomotor activity. Although marked increases in locomotor activity were measured during the first 10 min following administration of *d*-methamphetamine at 10 mg/kg, this dose did not significantly augment cumulative locomotor activity during the entire 2-h period (Fig. [1](#Fig1){ref-type="fig"}b). However, *d*-methamphetamine-treated mice showed intense stereotyped behaviors (e.g., biting or licking) without traveling, even beyond the 2-h period. The stereotyped behaviors were evaluated at the same doses. *d*-Methamphetamine induced stereotyped behaviors in a dose-dependent manner, whereas *l*-methamphetamine did not (Fig. [1](#Fig1){ref-type="fig"}c). This result suggests that the decreased locomotor activity in mice treated with 10 mg/kg of *d*-methamphetamine may be due to the induction of strong stereotyped behaviors. Moreover, mice repeatedly administered *l*-methamphetamine did not develop behavioral sensitization, whereas repeated exposure to *d*-methamphetamine led to hyperlocomotion at a level exceeding that induced following the initial administration (Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1*d*-Methamphetamine, but not *l*-methamphetamine, at doses of 1--10 mg/kg induces psychomotor activity. Cumulative counts (**a**) and temporal change (**b**) in locomotor activity in mice for 2 h following a single administration of saline, *l*-methamphetamine (*l*-MAMP), or *d*-methamphetamine (*d*-MAMP) at doses of 1--10 mg/kg. **c** Cumulative 2-h scores for stereotyped behaviors in mice treated with *l*- or *d*-methamphetamine (1--10 mg/kg). **d** Sensitization following repeated administration of *l*- or *d*-methamphetamine (2 mg/kg). Each value represents mean ± SEM (**a**, **c**, and **d**) or mean (**b**). (**a** and **b**, *n* = 12; **c**, *n* = 9; **d**, *n* = 7--8). \**P* \< 0.05, \*\**P* \< 0.005 and \*\*\**P* \< 0.0005 vs. saline-treated mice (**a**, **c**), or vs. the first administration in each group (**d**)

Pharmacokinetics {#Sec11}
----------------

We next investigated whether differences in plasma or brain pharmacokinetic parameters reflected the intensity of the psychomotor effects. Values of plasma *C* ~max~ and AUC~0--4h~ following administration of 1 mg/kg *d*-methamphetamine were comparable with those for 1 mg/kg *l*-methamphetamine (Table [1](#Tab1){ref-type="table"}). Mice were administered 1 mg/kg of *d*-methamphetamine s.c. (a dose that induced psychomotor activity) or 10 mg/kg (s.c.) of *l*-methamphetamine (the maximum dose used in the behavioral tests). Plasma *C* ~max~, AUC~0--2h~, and striatal concentrations of methamphetamine and amphetamine following administration of *l*-methamphetamine were ≥10-fold those post *d*-methamphetamine administration. These results indicate that the distinctive psychomotor effects of *d*- and *l*-methamphetamine are not due to differences in their plasma or striatum pharmacokinetics.Table 1Pharmacokinetic parameters and brain concentrations of methamphetamine and amphetamine in mice following subcutaneous administration of *l*-methamphetamine or *d*-methamphetamineExp. no.TissueAnalyteParameterDrug administered*l*-MAMP (1 mg/kg)*d*-MAMP (1 mg/kg)IPlasmaMAMP*C* ~max~ (μg/mL)0.062 ± 0.0070.072 ± 0.013AUC~0--4 h~ (μg·h/mL)0.1290.159*l*-MAMP (10 mg/kg)*d*-MAMP (1 mg/kg)IIPlasmaMAMP*C* ~max~ (μg/mL)0.988 ± 0.034\*0.093 ± 0.008AUC~0--2 h~ (μg·h/mL)1.66 ± 0.06\*0.142 ± 0.008AMP*C* ~max~ (μg/mL)0.067 ± 0.005\<0.003^a^AUC~0--2 h~ (μg·h/mL)0.092 ± 0.008N.C.BrainMAMPConc. (μg/g tissue)1.99 ± 0.06\*0.126 ± 0.008AMPConc. (μg/g tissue)0.212 ± 0.013\*0.006 ± 0.001Blood samples were collected at 0.08, 0.17, 0.33, 0.5, 1, 1.5, 2, 3 and 4 h (Exp. I), and 0.17, 0.33, 0.5, 1, 1.5, and 2 h (Exp. II) post-drug administration. Each value represents mean or mean ± SD (3--4 mice per time-point; Exp. I), or mean ± SEM (6 mice per group; Exp. II)*MAMP* methamphetamine, *AMP* amphetamine, *AUC* ~*0--2h*~ *and AUC* ~*0--4h*~ area under the plasma concentration vs. time curve from 0 to 2 or 4 h, *C* ~*max*~ maximum plasma concentration, *Conc.* concentration, *N.C.* not calculated\* *P* \< 0.05 vs. *d*-methamphetamine-treated group^a^Below the lower limit of quantitation (3 ng/mL)

Discussion {#Sec12}
==========

There have been no studies directly comparing the pharmacodynamics and pharmacokinetics of the methamphetamine enantiomers in mice. It is often suggested that *d*-methamphetamine exerts more potent physiological and pharmacological effects than *l*-methamphetamine does, and that the stimulating effects exerted by *l*-methamphetamine on the central nervous system are 2--10 times less potent than those of *d*-methamphetamine (Mendelson et al. [@CR6]). The results of the present study indicated that psychostimulant effects induced by *l*-methamphetamine are lower than those elicited by one-tenth the dose of *d*-methamphetamine. In addition, plasma pharmacokinetic parameters and striatal concentrations of methamphetamine following administration of *l*-methamphetamine at 10 mg/kg (which did not induce psychomotor activity) were approximately 11 and 16 times as high, respectively, as those following administration of 1 mg/kg *d*-methamphetamine. Despite the fact that there are differentiable psycho-stimulating effects between two enantiomers, no significant difference in plasma pharmacokinetic parameters was detected at 1 mg/kg. In comparative positron emission tomography studies, the pharmacokinetics in the baboon brain was comparable for ^11^C-*d*- and ^11^C-*l*-methamphetamine (Fowler et al. [@CR4]). Thus, factors other than brain or plasma pharmacokinetics, especially differences in the affinity of each enantiomer for its pharmacological targets, may account for the more potent psychomotor effects of *d*-methamphetamine. For instance, the effects of *d*-methamphetamine on the release and uptake of dopamine in rat caudate synaptosomes are reportedly approximately 17- and 42-fold greater, respectively, than those of *l*-methamphetamine (Rothman et al. [@CR10]). Kuzcenski et al. ([@CR5]) demonstrated that the peak dopamine concentration in rat caudate following s.c. administration of 2 mg/kg *d*-methamphetamine is approximately 2.3 times as high as that after administration of 12 mg/kg *l*-methamphetamine. Comparative studies to differentiate the affinities of the enantiomers to target molecules will be required to clarify the mechanisms that give rise to the difference in psychomotor efficacies between *d*- and *l*-methamphetamine.

Selegiline is sometimes regarded as an inducer of psychoactive effects through its metabolites having a component of *N*,α-dimethyl-*N*-2-propynyl phenethylamine. Previous clinical studies have reported that the *C* ~max~ of *l*-methamphetamine following administration of conventional selegiline tablets 10 mg (Clarke et al. [@CR2]) was fivefold lower than the *C* ~max~ observed in methamphetamine abusers who had received intravenous *l*-methamphetamine at a dose of 0.25 mg/kg, which does not exert psychoactive effects (Mendelson et al. [@CR6]). Thus, the results of these previous reports suggest that the *l*-methamphetamine available as a metabolite after selegiline administration at clinical doses may have little potential to induce psychoactive effects.

Taken together, our results indicated that the psychostimulant effects elicited by *d*-methamphetamine are at least 10 times stronger than those induced by *l*-methamphetamine based on their doses for inducing psychomotor activities. Furthermore, the distinct psychoactive efficacies of the enantiomers are not due to differences in plasma pharmacokinetics or brain concentrations of methamphetamine/amphetamine following administration of the respective enantiomers.
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